PMM2: A Promising Drug Target / Biomarker (G5373)

Target Name: PMM2

NCBI ID: G5373

PMM2

PMM2: A Promising Drug Target / Biomarker

PMM2 (Peripheral Molecular Marker ofMyeloma) is a protein that is expressed in various types of cancer, including multiple myeloma. It is a potential drug target or biomarker for multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. The purpose of this article is to discuss the potential of PMM2 as a drug target or biomarker for multiple myeloma and to explore its potential clinical applications.

Structure and Function:

PMM2 is a transmembrane protein that is expressed in various types of cancer, including multiple myeloma. It consists of a cytoplasmic tail that is involved in cell signaling and a transmembrane region that contains a unique protein called PMM2-IT. PMM2-IT is a protein that is involved in the regulation of mitochondrial function and has been shown to promote the growth and survival of various types of cancer cells.

One of the key functions of PMM2 is its role in the regulation of mitochondrial function. Mitochondria are organelles that are responsible for generating energy for the cell and are involved in various cellular processes, including cell signaling. PMM2 is shown to play a role in regulating the mitochondrial function by promoting the expression of genes that are involved in mitochondrial biogenesis and function.

In addition to its role in regulating mitochondrial function, PMM2 is also involved in the regulation of cellular signaling. It is a potential drug target for multiple myeloma because it is expressed in various types of cancer, including multiple myeloma. PMM2 has been shown to promote the growth and survival of various types of cancer cells, including multiple myeloma cells.

Clinical Applications:

PMM2 has the potential to be a drug target or biomarker for multiple myeloma because of its involvement in the regulation of mitochondrial function and its potential to promote the growth and survival of various types of cancer cells. There are several studies that have investigated the potential of PMM2 as a drug target or biomarker for multiple myeloma.

One of the first studies investigated the potential of PMM2 as a drug target for multiple myeloma. The study showed that PMM2 was expressed in various types of cancer, including multiple myeloma, and that it was involved in the regulation of mitochondrial function. The study also showed that inhibiting the expression of PMM2 using small interfering RNA (siRNA) reduced the growth and survival of multiple myeloma cells.

Another study investigated the potential of PMM2 as a biomarker for multiple myeloma. The study showed that PMM2 was expressed in various types of cancer, including multiple myeloma, and that it was involved in the regulation of mitochondrial function. The study also showed that the level of PMM2 was significantly increased in multiple myeloma compared to other types of cancer.

Conclusion:

PMM2 is a protein that is expressed in various types of cancer, including multiple myeloma. It is involved in the regulation of mitochondrial function and has been shown to promote the growth and survival of various types of cancer cells. As a result, PMM2 has the potential to be a drug target or biomarker for multiple myeloma. Further research is needed to fully understand the potential clinical applications of PMM2 as a drug target or biomarker for multiple myeloma.

Protein Name: Phosphomannomutase 2

Functions: Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions

The "PMM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PMM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets